Metformin boosts survival in men with diabetes, prostate cancer

08/6/2013 | MedPage Today (free registration)

Metformin use was associated with a 24% lower risk of all-cause mortality during the first six months of treatment in men with diabetes and prostate cancer compared with nonusers, a study indicated. Researchers also found that each additional six-month period of metformin treatment was tied to 44% lower odds of prostate cancer-specific mortality and a 20% decreased risk of all-cause mortality. The results appear in the Journal of Clinical Oncology.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ